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Abstract
Purpose—Data sharing through ClinVar offers a unique opportunity to identify interpretation 
differences between laboratories. As part of a ClinGen initiative, four clinical laboratories (Ambry, 
GeneDx, Partners Healthcare Laboratory for Molecular Medicine, and University of Chicago 
Genetic Services Laboratory) collaborated to identify the basis of interpretation differences and to 
investigate if data sharing and reassessment resolves interpretation differences by analyzing a 
subset of variants.
Methods—ClinVar variants with submissions from at least two of the four participating 
laboratories were compared. For a subset of identified differences, laboratories documented the 
basis for discordance, shared internal data, independently reassessed with the ACMG-AMP 
guidelines, and then compared interpretations.
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Results—6,169 variants in ClinVar were interpreted by at least two of the participating 
laboratories, of which 88.3% were initially concordant. Laboratories reassessed 242/724 initially 
discordant variants, of which 87.2% (211) were resolved by reassessment with current criteria 
and/or internal data sharing. 12.8% (31) of reassessed variants remain discordant due to 
differences in application of the ACMG-AMP guidelines.
Conclusion—Participating laboratories increased their overall concordance from 88.3% to 
91.7%, indicating that sharing variant interpretations in ClinVar, allowing identification of 
differences and motivation to resolve those differences, is critical to move toward more consistent 
variant interpretations.
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ClinVar; variant interpretation; data sharing; ACMG-AMP guidelines
INTRODUCTION
Interpreting the clinical significance of genetic variants is a challenging process that involves 
gathering and assessing available evidence, followed by formal classification based on this 
evidence. Variant classifications from laboratories may confirm the cause of disease, 
illuminate an etiology not previously considered, or guide treatment decisions. Historically, 
variant classifications from clinical laboratories have mostly been unavailable to the larger 
genetics community except for the small fraction published in journals. Recent efforts by the 
National Institute of Health (NIH) funded Clinical Genome Resource (ClinGen; https://
www.clinicalgenome.org/) to support widespread data sharing using the ClinVar database 
has accelerated the public sharing of interpreted variants, particularly by clinical 
laboratories.1 The ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/), maintained by 
the National Center for Biotechnology Information (NCBI), archives and aggregates 
submitted interpretations of the clinical significance of variants, with opportunities for each 
submitter to provide supporting evidence, and indicates if the submitted interpretations are 
concordant or discordant.2 Sharing variants in ClinVar allows for crowd-sourcing the 
enormous labor of variant interpretation and provides transparency and inherent “peer 
review” of variant classifications. Additionally, sharing data facilitates identification of 
differences in variant interpretation, allowing a valuable opportunity for clinical laboratories 
and other ClinVar submitters to resolve those differences.
Prior reports of inconsistencies in variant interpretations have ranged from 53% discordance 
in double review of pathogenic or likely pathogenic variants3, 53% discordance of uncertain 
significance interpretations from one clinical laboratory compared to another4, and 60% 
discordance of a single laboratory’s interpretations to other clinical laboratories5. However, 
these comparisons likely overestimate discordance as most compare a current interpretation 
to historic interpretations from other source(s), which may be outdated and not based on an 
assessment of the same evidence. Reported discordant counts are typically limited to one- or 
two-step differences between the three major classification levels: “pathogenic (P)/likely 
pathogenic (LP)”, “uncertain significance (VUS)”, and “likely benign (LB)/benign (B)”. 
Differences in confidence or “likelihood” are not included in these discordant counts as they 
are unlikely to impact clinical care and are not reported as conflicts in ClinVar.2,7 
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Differences in variant interpretations between clinical laboratories often occur due to 
differences in algorithms for weighing evidence to reach a classification or differences in 
available evidence, such as internal frequency and data or access to proprietary databases. A 
recent report found that 33% of interpretation differences between clinical laboratories were 
due to lack of access to privately held data.5
Historically, clinical laboratories had developed their own internal methods for variant 
assessment and classification, and some relied heavily upon claims in the peer-reviewed 
literature, both contributing to inconsistencies in variant classification between laboratories. 
In 2015, the American College of Medical Genetics and Genomics (ACMG) and the 
Association for Molecular Pathology (AMP) published a joint guideline for variant 
interpretation that provides an evidence-based framework to classify variants, requiring 
laboratories to critically review literature claims and base classifications on a review of the 
primary evidence.8 By including a defined set of evidence types, the ACMG-AMP 
guidelines enable tracking of the specific evidence types and strengths used to classify each 
variant, which facilitates classification rationale transparency and accurate classification 
comparisons. However, given the complexity of variant interpretation, application of the 
criteria still requires subjective interpretation. A recent study piloting the 2015 ACMG-AMP 
guidelines across nine sites involved in the Clinical Sequencing Exploratory Research 
(CSER) program9 found that classifications were initially 43.4% (43/99) discordant but 
resolution was possible for 67.4% (29/43) of initial interpretation differences leaving only 
5% (5/99) of variants with medically significant differences (P/LP vs. VUS/LB/B) 
remaining at the conclusion of the study.7 This exercise, however, was performed before 
laboratories had operationally implemented the guidelines, and for the majority of variants, 
was not based upon variants encountered during routine clinical testing. In addition, in May 
2015, ClinVar was found to have 17% discordance in variants with multiple submitters, but 
this discordance is also based on all interpretations submitted to ClinVar, which includes 
interpretations from research laboratories, locus-specific databases, and aggregate databases 
(Online Mendelian Inheritance in Man [OMIM] and GeneReviews).1 Therefore, we sought 
to examine variant interpretation concordance in the routine clinical laboratory environment.
Four clinical laboratories, Ambry Genetics, GeneDx, Partners HealthCare Laboratory for 
Molecular Medicine (LMM), and University of Chicago Genetic Services Laboratories 
(UCGSL), are working together to identify interpretation differences after submission to 
ClinVar and collaborate to resolve these differences by data sharing and reassessment with 
laboratories’ current criteria, consistent with ACMG-AMP guidelines. While complete 
concordance in interpretations is unlikely due to subjectivity in weighting evidence and 
interpretation of guidelines, our goal was to track detailed data on a subset of all 
interpretation differences to identify trends regarding the basis of interpretation differences 
between laboratories and investigate the ability of laboratories to resolve differences in 
variants already clinically reported, which will educate the community on how to move 
towards more consistent variant interpretations.
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MATERIALS AND METHODS
ClinVar Data Analysis
A custom report was generated by ClinVar on January 6, 2016 to identify all alleles 
(measure_ids) in ClinVar with submissions from at least two of the four participating 
laboratories (Ambry, GeneDx, LMM, and UCGSL) and report the interpretations from all 
participating laboratories for each identified allele. For each allele, interpretations were 
compared to determine concordance or discordance; and if discordant, the level of 
discordance was assigned. For variants with greater than two interpretation terms submitted, 
the two most discordant terms were used to assign the level of discordance. For example, a 
variant with a pathogenic, likely pathogenic, and uncertain significance interpretation would 
be categorized by the pathogenic vs. uncertain significance difference. Metrics were 
calculated for all four laboratories in aggregate as well as each pair-wise comparison of the 
four laboratories to facilitate identification of variants for reassessment.
Resolution Process
Each laboratory compared their interpretations in ClinVar to their current internal 
interpretations to determine if the difference was resolved by a more recent reassessment not 
yet represented in ClinVar. Next, each pair of laboratories identified a subset of variants with 
interpretation differences for reassessment (242 variants of the total 724 variants with 
interpretation differences), prioritizing variants with P/LP vs. LB/B differences, followed by 
additional medically significant differences, and genes and/or disease areas with a higher 
frequency of interpretation differences. After identifying variants for reassessment, 
participating laboratories shared internal data, discussed initial classification rationale, and 
categorized the reason for the initial interpretation difference when it was apparent (e.g. 
differences in classifications rules or internal data). After discussion, laboratories 
independently reassessed variants with the ACMG-AMP guidelines and, if appropriate, 
reclassified the variant in their own database. Laboratories continued discussion for variants 
with interpretations that remained different after internal reassessment allowing consensus to 
be achieved for an additional set of discordant variants. For variants remaining discordant, 
any unique ACMG-AMP criteria applied by one laboratory but not the other participating 
laboratory was tracked. For statistical comparisons, a Fisher’s Exact test was used.
RESULTS
Initial Concordance Data
As of January 2016, over 49,000 unique variants had been submitted to ClinVar by at least 
one of the four participating laboratories (Ambry, GeneDx, LMM, and UCGSL). 
Comparison of data in ClinVar identified 6,169 variants from 308 genes interpreted by at 
least two of the four participating laboratories. This large number of variants interpreted by 
at least two participating clinical laboratories facilitated comparison of interpretations and 
potential resolution of differences.
Of the 6,169 shared variants (Figure 1A), 88.3% of interpretations between laboratories 
were concordant, with 62.3% (3,845 variants) in exact agreement and 26.0% (1,600 variants) 
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differing only in confidence levels (P vs. LP and LB vs. B). As confidence differences are 
unlikely to impact clinical care or management, they were not considered discordant for this 
project, and are included in concordant counts. The remaining 11.7% (724) of shared 
variants had discordant interpretations and were categorized by the level of discordance. 
3.5% (216 variants) of all shared variants were medically significant differences (MSDs), 
pathogenic (P/LP) versus other (VUS/LB/B), that are most likely to impact medical 
management; however, the majority of MSDs (94.4%) were P/LP versus VUS differences 
and only 12 variants of this set (5.6%) had P/LP versus LB/B differences. The remaining 
8.2% (508 variants) of all shared variants were VUS versus benign (LB/B) differences, 
which are less likely to affect medical management, but may lead to differences in 
counseling time and medical management. Analysis of concordance and discordance by 
variant type showed highest concordance (97.0%; 479/494) for interpretation of predicted 
null variants (nonsense, frameshift, and +/−1,2 splice site) with these differences accounting 
for only 0.8% (4/508) of all VUS vs LB/B differences and 5.1% (11/216) of all MSDs. 
Interpretation of missense variants were 84.6% concordant (3,053/3,607) but, as expected, 
missense differences accounted for the highest percent of both VUS vs LB/B differences 
(70.9%; 360/508) and MSDs (89.8%; 194/216).
The 724 variants with interpretation differences were from 148 genes. To determine trends 
by disease area, genes were categorized into four categories (cardiovascular, hereditary 
cancer, neurologic, and other) and the proportion of MSDs and other differences are shown 
in the first column for each disease area (“Total”; Figure 2). See Supplemental Table 1 for 
pre and post-resolution concordance rates in each disease area. The neurologic disease area 
had the lowest initial concordance (81.2%) with the majority of differences being VUS vs. 
LB/B compared to MSDs (17.8% and 1.0% of all neurologic variants, respectively). 
Cardiovascular was the only disease area with more initial MSDs than VUS vs. LB/B 
differences (5.9% and 5.2% of all cardiovascular variants, respectively). A summary for each 
of the 148 genes with interpretation differences, including the number of shared variants and 
percent concordant versus discordant, is provided in Supplemental Table 2.
Interpretation Differences Resolution
To facilitate resolution of interpretation differences between laboratories, each pair-wise 
combination of the four participating laboratories were compared to determine the number 
of interpretation differences from each pair of laboratories (Supplemental Table 3). 
Laboratory pairs with a higher number of total interpretation differences selected variants for 
reassessment based on level of discordance (prioritizing variants with medically significant 
differences, especially those with P/LP vs. LB/B differences) and by disease area, with 
cardiovascular reassessments prioritized by genes with multiple interpretation differences 
(MYBPC3, GLA, ACTC1, MYL2, MYL3, TPM1, RAF1) and hereditary cancer 
reassessments prioritized by variants in high-risk hereditary breast and ovarian cancer genes 
or genes with National Comprehensive Cancer Network (NCCN) criteria for management 
(BRCA1, BRCA2, CDH1, PTEN, TP53). Laboratory pairs with lower total interpretation 
differences prioritized variants for reassessments simply based on the level of discordance. 
In total, laboratories reassessed 242 variants with interpretation differences (116 variants 
with MSDs and 126 variants with other differences) to determine if sharing internal data and 
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applying the ACMG-AMP criteria and classification rules could resolve the different 
interpretations (Figure 3).
For the 116 reassessed variants with MSDs, 79.3% (92 variants) were resolved by 
reassessment, data sharing and discussion with 19.8% (23 variants) resolved as P/LP, 58.6% 
(68 variants) resolved as VUS, and 0.9% (1 variant) resolved as LB. For the 126 reassessed 
variants with VUS vs. LB/B differences, 94.4% (119 variants) were resolved with 16.7% (21 
variants) resolved as VUS and 77.8% (98 variants) resolved as LB/Bn. In total, 211 of 242 
reassessed variants (87.2%) were resolved. Comparing disease areas (Figure 2), laboratories 
had a significantly higher resolution rate for cardiovascular variants than hereditary cancer 
variants (p=0.00059) and neurologic variants (p=0.027); no significant differences were 
observed between hereditary cancer and neurologic variants (Figure 2). The difference 
between cardiovascular and hereditary cancer resolution rates is due to a significantly higher 
resolution rate specifically for cardiovascular MSDs (74/77) versus hereditary cancer MSDs 
(17/32; p=0.0001). No significant differences in resolution of VUS vs LB/B interpretation 
differences were observed between disease areas. See Supplemental Table 4 for a full list of 
resolved variants. As classifications may change over time with available evidence, please 
check ClinVar for the most up-to-date classifications.
For a subset of variants with resolved interpretation differences (100 variants), the reason for 
the initial interpretation differences and whether reassessment with ACMG/AMP guidelines 
and/or sharing internal evidence impacted the re-classification were both documented 
(Figure 4). For each variant, laboratories decided which of the pre-defined categories best 
explained the initial difference in interpretation. Reassessment of older variant 
interpretations with updated classification criteria, consistent with ACMG-AMP guidelines, 
resolved 36% of variants (Figure 4, red shading). Sharing internal data facilitated resolution 
of 33% of resolved variants (blue shading), with sharing segregation data (10%) and co-
occurrence data (9%) facilitating the largest percent of variants. Differences in the use or 
weighting of public data accounted for 14% of interpretation differences (purple shading), 
including benign/likely benign thresholds (9%), and different data sources (5%). Lastly, for 
17% of resolved variants, the interpretation differences were found to have already been 
resolved but the new interpretations were not yet submitted to ClinVar.
Persistent Interpretation Differences
After reassessment and data sharing, laboratories were unable to reach consensus for 12.8% 
(31 variants) of the 242 reassessed variants, of which 24 are unresolved MSDs and 7 are 
unresolved other differences (Supplemental Table 5). For all unresolved differences, 
reassessments from the submitting laboratories were compared to determine the unique 
ACMG-AMP criteria applied that accounted for the different clinical interpretations (Table 
1). Unique ACMG-AMP criteria applied were then grouped into evidence categories, as 
used in Richards et al 2015 Figure 18, to determine if specific categories of evidence were 
more likely to be differently applied than others. For the persistent MSDs, 50% (12 variants) 
were impacted by differences in the application of benign criteria, such as: minor allele 
frequency data (BS1), observation in unaffected adults (BS2), and functional studies 
showing no deleterious effect (BS3). The remaining persistent MSDs were due to different 
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application of pathogenic criteria, with evidence in the functional data category impacting 
the highest percent of variants. For the 7 variants with unresolved VUS vs. LB/B differences 
(Table 1), the most frequent differentially applied ACMG-AMP criteria was minor allele 
frequency data (BS1). In total, across both discordant types, evidence in the functional data 
category (48%) and population data category (45%) contributed to the highest number of 
persistent interpretation differences.
Additionally, even though interpretations remained discordant, for 7 variants, reassessment 
reduced the level of discordance from a two-step difference (P/LP vs. B/LB) to a one-step 
difference (P/LP vs. VUS or VUS vs. LB/B). These variants are highlighted in grey in 
Supplemental Table 5.
DISCUSSION
Data sharing through ClinVar offers a unique opportunity to identify classification 
differences between laboratories and to collaborate to resolve these differences. By 
submitting variant interpretations to ClinVar and working together, four clinical laboratories 
were able to resolve differences in 87.2% of initially discordant variants that were reviewed 
(211/242 variants). With only 33.4% of all variants with interpretation differences reviewed 
so far (242/724 variants), participating laboratories have already increased their overall 
concordance rate from 88.3% to 91.7% (Figure 1B), indicating that sharing internal evidence 
and classification rationales is critical to move toward more consistent variant 
interpretations. This concordance rate is higher than previous reports because the scope was 
limited to a set of four clinical laboratories, as opposed to a report of 77% concordance 
between all ClinVar submitters of a set of variants6, and because participating laboratories 
shared all evidence such that interpretations are based on the same set of evidence, as 
opposed to a report of only 40% concordance between laboratories when internal data was 
not shared5. Additionally, both initial concordance (88.3%) and resolution rate (87.2%) are 
higher than reported by the nine sites in the CSER program (56.6% and 72.5%, 
respectively)7 as the majority of selected CSER variants were outside the scope of variants 
and genes encountered by the CSER sites during routine clinical testing, suggesting that 
expertise in disease areas may contribute to increased concordance.
Implementation of the evidence-based 2015 ACMG-AMP guidelines for sequence variant 
interpretation has alleviated some burden of differences due to classification algorithms. 
Thirty-six percent of resolved variants were initially discordant due to differences in each 
laboratory’s internal classification method used at the time of initial assessment but the 
interpretation differences were resolved by reassessment with laboratories’ current criteria, 
consistent with ACMG-AMP guidelines. However, implementation of the ACMG-AMP 
guidelines still requires professional judgment in deciding which evidence types are met, as 
12.8% of variants reassessed with the guidelines were unable to be resolved. It is important 
to note that for the persistent interpretation differences, laboratories had access to the same 
data, including shared internal data; however, the interpretation of that data in the context of 
meeting specific ACMG-AMP criteria differed. The majority of persistent interpretation 
differences were due to differences in the application of functional data (48%) and 
population data (45%), both of which require gene or disease-specific knowledge. 
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Differences in the application of these criteria suggest that further gene specification of the 
ACMG-AMP guidelines by experts, such as providing specific allele frequency cutoffs and 
indicating which functional assays are considered well-established, could increase 
concordance. Specifically, comparison of the reassessment outcome between four disease 
areas indicates that genes in the inherited cancer disease area would greatly benefit from 
ACMG-AMP specification as this disease area had the lowest rate of resolution (78%) and 
highest rate of persistent medically significant interpretation differences (Figure 2; 
Supplemental Table 1). Recent publications have provided feedback and recommendations 
for the ACMG-AMP guidelines.7,10,11 ClinGen disease-specific working groups and the 
ClinGen Sequence Variant Interpretation working group are focused on specifying the 
ACMG-AMP guidelines for diseases of interest, including minor allele frequency 
thresholds, gene-specific functional assay and domain data, as well as providing further 
quantitative guidance on individual criteria such as segregation data, population data and 
case data. These recommendations will become public once completed and approved by 
ClinGen.
Our analyses demonstrated that resolution of 33% of variant interpretation differences 
benefited from sharing internal data. To date, such data has been typically inaccessible 
except for the small subset of data published in the literature, often many years after it was 
identified. This leads to important information that could affect patient diagnoses being 
unavailable to those individuals who could benefit. However, through submission to ClinVar, 
laboratories can more quickly share this data as it accumulates, allowing other laboratories 
and the patients they serve to benefit. It should be noted that some, but not all, clinical 
laboratories provide detailed supporting evidence in ClinVar, in the form of citations, text-
based interpretation summaries, and case-level observations. Still, even for laboratories that 
have not yet shared this detail, ClinVar submissions at least identify that a laboratory has 
observed the variant and prompts further collaborative investigations and data sharing when 
patient treatment decisions could be impacted.
Over a third of the variant interpretation differences were resolved simply by one laboratory 
reassessing an old variant interpretation with the laboratory’s current criteria, consistent with 
ACMG-AMP guidelines. Most clinical laboratories reassess variants when that variant is 
observed in an additional case or at the request of providers. Thus, for many remaining 
interpretation differences not yet reviewed, routine clinical laboratory reassessment with 
current criteria will resolve the difference regardless of sharing internal evidence. While 
these recommendations will benefit some variants, many variants identified in Mendelian 
disease testing are extremely rare1 underscored by the observation that 88% of the 49,734 
unique variants in this study were submitted by only one of the four laboratories. In addition, 
analysis of the sequencing data from 60,706 individuals in the Exome Aggregation 
Consortium (ExAC) found that 99% of identified high-quality variants have an allele 
frequency less than 1% and 54% of identified high-quality ExAC variants are only seen once 
in the entire dataset.12 These findings further emphasize that the vast majority of variants 
identified by clinical testing laboratories are incredibly rare or even private and thus are 
unlikely to be regularly reassessed or potentially ever interpreted again. Therefore it is 
critical that laboratories share their observations and identify differences which may be the 
only prompt for reassessment.
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Differences in interpretation of data are not unique to clinical genetic laboratories, as other 
healthcare providers are also subject to discordance in professional interpretation. When 
comparing pathologists’ interpretations of individual breast biopsies to consensus-derived 
reference diagnosis, the overall concordance was only 75.3%.13 Similarly, radiologists were 
only 83% concordant in assessing dense versus nondense status of breast mammograms.14 
These findings suggest that a consensus-based approach of multiple experts collaborating on 
a diagnosis may be necessary to improve interpretation. Similar approaches have been seen 
in rare disease genetics with the formation of international expert consortia that can provide 
consensus interpretations of variants, such as the International Society for Gastrointestinal 
Hereditary Tumours (InSiGHT) and Evidence-based Network for the Interpretation of 
Germline Mutation Alleles (ENIGMA).15,16 These disease-focused efforts not only apply 
expert interpretation but can organize data gathering efforts and spur research studies that 
can lead to a better understanding of genetic variation in their respective domains. For 
example, InSiGHT reclassified 54% of variants submitted with uncertain significance 
interpretations to pathogenic or likely pathogenic.15 To expand these efforts, ClinGen has 
formed numerous disease expert groups (https://www.clinicalgenome.org/working-groups/
clinical-domain/) and continues to solicit further applications from groups to be considered 
as expert panels (three star level) with respect to their ClinVar submission status (http://
www.ncbi.nlm.nih.gov/clinvar/docs/review_guidelines/). Once a three or four star variant 
interpretation is submitted to ClinVar from an experts, it will override submissions of lower 
review status to continually improve the reliability of public databases for use in diagnosis. 
However, these efforts heavily benefit from single lab submissions to identify variants that 
should be subject to expert review.
Laboratories did not reassess all 724 variants with interpretation differences as the goal of 
this pilot project was to determine if sharing internal data and implementing the ACMG-
AMP guidelines could resolve difference and to setup a framework for addressing all 
differences in ClinVar. In continuing to reassess the remaining variants with interpretation 
differences between these four clinical laboratories, further emphasis will be placed on 
engaging additional ClinVar submitters. To promote more consistent variant interpretations 
in this field, participation from all submitters on a variant with conflicting interpretations is 
necessary to move more variants from a single-star review status to a two-star review status 
indicating that all submitted interpretations of a variant are concordant. This process will be 
overseen by ClinGen’s Sequence Variant Inter-Laboratory Resolution working group, which 
will work on addressing all interpretation differences in ClinVar from all submitters. The 
lessons learned from this pilot project will guide the support and infrastructure needed to 
identify differences and facilitate sharing of internal data and classification rationale. For 
instance, in this study we found that 36% of interpretation differences were resolved simply 
by reassessing an older interpretation with laboratories’ updated classification criteria. Given 
the time commitment to this project (an estimated 1–2 hours per variant per laboratory), 
future resolution will begin by encouraging laboratories with older interpretations or outlier 
interpretations to first reassess the variant with current guidelines, which would minimize 
the total time commitment for all laboratories.
In conclusion, these results demonstrate that clinical interpretations from these four clinical 
laboratories are now concordant for 91.5% of shared variants in ClinVar, with only 2% of 
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variant interpretation differences considered medically significant. Further specification 
regarding gene-specific criteria and expert guidance on the relevance of conflicting 
pathogenic and benign criteria may further facilitate resolution of interpretation differences 
with ACMG-AMP guidelines. Given that the interpretation of variants for their role in 
disease requires expert opinion and subjective review of scientific evidence and medical 
data, complete concordance is not expected. However, increased training and guidance on 
the application of the ACMG-AMP criteria and ensuring full sharing of evidence and 
classification rationales, is critical to move toward more consistent variant interpretations 
which will improve the care of patients with, or at risk for, genetic disorders.
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Figure 1. Distribution of variant interpretation comparisons between four clinical laboratories
(A) Interpretation comparison of data in ClinVar (as of January 1, 2016), pre-resolution 
efforts
(B) Interpretation comparison after reassessing 33% (242/724) of shared variants with 
interpretation differences
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Figure 2. Distribution of interpretation differences and resolution outcome per disease areas
Distribution of medically significant (P/LP vs VUS/LB/B) and other (VUS vs LB/B) 
differences within each disease area for all initial differences (“Total”), variants reassessed 
by laboratories (“Reassessed”), and final outcome for reassessed variants, including 
proportion resolved (“Outcome”).
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Figure 3. 
Flowchart and outcome of variant resolution efforts.
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Figure 4. Basis of initial interpretation differences for resolved variants
Over half of the initial interpretation differences were resolved simply because the re-
interpretation had already been completed but was not yet submitted to ClinVar (17%, 
yellow shading) or by reassessing an old variant interpretation with the laboratory’s updated 
classification criteria, consistent with ACMG-AMP guidelines (36%, red shading). 
Differences in the use or weighting of public data accounted for 14% of interpretation 
differences (purple shading), including benign/likely benign thresholds (9%), and different 
data sources (5%). Differences in internal data accounted for 33% of interpretation 
differences (blue shading), including segregation data (10%), co-occurrence data (9%), 
internal proband frequency (8%), and detailed phenotype data (6%).
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